

Peer Review

Review of: "Gestational Inflammation: Its Foetal Control and the Proper Therapeutic Approach"

Emilio Giugliano¹

1. University of Ferrara, Italy

The inflammatory balance is the basis of the development of numerous medical pathologies and is fundamental in the development of a physiological pregnancy. The proposed therapeutic approach is acceptable and is based on important immunological knowledge^[1]. It is important to send the message that high-risk pregnancies should be treated right from the start. Balancing gestational inflammation is essential to reduce the rate of miscarriage but above all to reduce the rate of obstetric complications.

A recent meta-analysis also confirms these statements ^[2], demonstrating how the use of oral corticosteroids significantly increases the pregnancy rate beyond 12 weeks in groups of patients with a history of recurrent abortions.

A similar anti-inflammatory/immunosuppressive approach is also the subject of debate in the field of reproductive medicine. The use of certain drugs that interact more specifically in inflammatory processes could represent new therapeutic options in the near future^[3]

For all these reasons the article should be accepted as a review

References

1. [△]Wenjuan Wang, Nayoung Sung, Alice Gilman-Sachs, Joanne Kwak-Kim. (2020). T Helper (Th) Cell Profiles in Pregnancy and Recurrent Pregnancy Losses: Th1/Th2/Th9/Th17/Th22/Tfh Cells. Front. Immunol., vol. 11 . doi:10.3389/fimmu.2020.02025.
2. [△]Silvia D'Ippolito, Filippo Gavi, Chiara Granieri, Chiara De Waure, et al. (2025). Efficacy of Corticosteroids in Patients With Recurrent Pregnancy Loss: A Systematic Review and Meta-Analysis. American J Rep I

mmunol, vol. 93 (1). doi:10.1111/aji.70037.

3. [^]Mauro Cozzolino, Livia Pellegrini, Silvio Tartaglia, Silvia Mancuso, et al. (2024). Subcutaneous G-CSF administration improves IVF outcomes in patients with recurrent implantation failure presenting a KIR/HLA-C mismatch. *Journal of Reproductive Immunology*, vol. 165 , 104310. doi:10.1016/j.jri.2024.104310.

Declarations

Potential competing interests: No potential competing interests to declare.